Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1 -- 1208 2024-02-26 22:32:47 |
2 Reference format revised. Meta information modification 1208 2024-02-27 01:39:08 |

Video Upload Options

Do you have a full video?

Confirm

Are you sure to Delete?
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Serés-Noriega, T.; Perea, V.; Amor, A.J. Physiopathology of Atherosclerosis in Type 1 Diabetes. Encyclopedia. Available online: https://encyclopedia.pub/entry/55493 (accessed on 23 April 2024).
Serés-Noriega T, Perea V, Amor AJ. Physiopathology of Atherosclerosis in Type 1 Diabetes. Encyclopedia. Available at: https://encyclopedia.pub/entry/55493. Accessed April 23, 2024.
Serés-Noriega, Tonet, Verónica Perea, Antonio J. Amor. "Physiopathology of Atherosclerosis in Type 1 Diabetes" Encyclopedia, https://encyclopedia.pub/entry/55493 (accessed April 23, 2024).
Serés-Noriega, T., Perea, V., & Amor, A.J. (2024, February 26). Physiopathology of Atherosclerosis in Type 1 Diabetes. In Encyclopedia. https://encyclopedia.pub/entry/55493
Serés-Noriega, Tonet, et al. "Physiopathology of Atherosclerosis in Type 1 Diabetes." Encyclopedia. Web. 26 February, 2024.
Physiopathology of Atherosclerosis in Type 1 Diabetes
Edit

People with type 1 diabetes (T1D) have a high cardiovascular disease (CVD) risk, which remains the leading cause of death in this population. Despite the improved control of several classic risk factors, particularly better glycaemic control, cardiovascular morbidity and mortality continue to be significantly higher than in the general population.

type 1 diabetes cardiovascular risk atherosclerosis

1. Introduction

Cardiovascular disease is the leading cause of mortality and morbidity worldwide. Although medical advances have reduced the incidence of death over the past decade, global prevalence and mortality have continued to rise [1]. Atherosclerotic cardiovascular disease (ASCVD), mainly coronary artery disease (CAD) and atherothrombotic stroke, represents the leading cause within this group, accounting for over 13 million deaths in 2021 [2].
Cardiovascular risk (CVR) is often assessed using various equations that estimate the 10-year probability of suffering an event. This strategy has several disadvantages: (1) most of them are not applicable in people aged <40 years, and age greatly influences the estimated risk, which makes it difficult to identify young people at high risk; (2) they are designed to use cross-sectional data, although the impact of the main risk factors occurs cumulatively; and (3) they consider only a few classical risk factors (e.g., sex, age, smoking habit, cholesterol levels or systolic blood pressure) and leave it to the clinician to decide how to weight the risk indicated by several other variables that modify CVR (e.g., social deprivation, the presence of obstetric factors or autoinflammatory diseases). Furthermore, there is no clear consensus between the different strategies. Several studies show heterogeneous recommendations depending on the equation used, and a lower than desired discriminatory power [3][4][5]. All this underlines the need for additional tools to better assess CVR in each individual.
The prelude to an acute event is the formation of atheromatous plaques in large and medium-sized arteries, which begins early in life and progresses silently over several years. The detection of subclinical atherosclerosis, which can be easily assessed using mostly non-invasive imaging tests, is one of the main strategies employed to individualise this risk. The presence of atheromatous plaques is associated with incident cardiovascular events in studies on large population cohorts without diabetes [6][7][8]. It allows us to identify young individuals at high CVR who may benefit from a long-term preventive strategy, knowing that they could benefit most from CVR control such as low-density lipoprotein cholesterol (LDLc) levels or blood pressure [9][10]. This is important because statins [11] and PCSK9 inhibitors [12][13] can delay the process of atherosclerosis, stabilise plaques already formed and reduce the likelihood of cardiovascular events. In this sense, the main clinical guidelines for cardiovascular prevention consider subclinical atherosclerosis detection as a risk-modifying factor, primarily in intermediate or borderline risk patients, both up- and down-regulating, with the consequent changes in treatment and follow-up that this entails [14][15]. In addition, the visualisation of atherosclerotic plaques by patients themselves is not only useful for the clinician but can also improve adherence to lifestyle measures and treatments with proven cardioprotective effects (e.g., lipid-lowering, antihypertensive and antiplatelet therapy) [16].
People with T1D have a four to eight times higher risk of CVD than the general population [17][18]. The physiopathology of T1D is characterised by the rapid and early autoimmune destruction of pancreatic beta cells, resulting in hyperglycaemia and the requirement for lifelong insulin replacement therapy. Hyperglycaemia is one of the most important CVR factors; however, even those with optimal glycaemic control (time-updated haemoglobin A1c (HbA1c) ≤ 6.9% or 51.9 mmol/mol) have a three-fold increased risk of CVD death compared with their counterparts without diabetes [19]. This fact suggests the existence of other factors involved in the pathogenesis of CVD in T1D such as exposure to hypoglycaemia, glycaemic variability, quantitative and qualitative abnormalities of lipoproteins, immune dysfunction, inflammation or cardiac autoimmunity, among others [20][21].

2. Physiopathology of Atherosclerosis in Diabetes

Atherosclerosis is a complex and not fully understood process. In brief, the evidence seems to state that it begins with the penetration and accumulation of apolipoprotein B-100-containing particles, mainly LDL particles, into the intimal layer of the arterial wall. In this new environment, they are oxidised and modified, leading to an inflammatory and immunogenic activation. Although the exact mechanisms are not fully understood, several processes, such as increased oxidative stress [22] and the degeneration of the endothelial glycocalyx [23], have been implicated. Subsequently, circulating T lymphocytes and monocytes enter the intimal layer through a dysfunctional endothelium. The latter mature into macrophages expressing scavenger receptors that recognise these modified lipoprotein particles and internalise them, notably increasing the cholesterol content of macrophages, turning them into foam cells. These foam cells release a plethora of proinflammatory cytokines that promote the process of atherosclerosis [24].
These leukocytes produce various mediators. The mediators cause smooth muscle cells to move from the media layer to the intima. There, the smooth muscle cells can grow and produce extracellular matrix molecules that increase the size of the plaque. From here, inflammation is perpetuated, and multiple processes occur that influence the progression of atherosclerosis. Finally, there are mainly two plaque complications: intraluminal growth with vascular stenosis and rupture or erosion with intravascular thrombus formation [25].
Various factors enhance and/or accelerate several of the above processes in people with diabetes. For example, hyperglycaemia leads to the glycation of various proteins, which undergo multiple reactions culminating in the formation of advanced glycation end products (AGEs). AGEs have been implicated in several steps in the development of atheromatous plaques, including accelerated monocyte migration, the glycation of lipoproteins facilitating the recognition by macrophages, an increased production of inflammatory cytokines and procoagulant effects, among others [26]. In addition, the increased productions of sorbitol and fructose (polyol pathway) also increase the production of AGEs. Further, AGEs are hardly degradable and may persist over time, which may explain why those who have had poor glycaemic control are at increased risk of vascular complications despite a better current control; this is known as the legacy effect [27][28].
Notwithstanding, through various mechanisms, mainly intracellular hyperglycaemia, there is an increase in oxidative stress with an increased production of reactive oxygen species, which react with various structures such as nucleic acids and proteins, increasing the expression of adhesion and inflammatory factors and affect genes involved in the pathogenesis of atherosclerosis [29][30]. There is an increased synthesis of pro-inflammatory cytokines in people with diabetes and several inflammatory markers have been associated with atherosclerosis in T1D [31][32][33]. In addition, elevated glucose levels and other processes increase the production of diacylglycerol, which, together with calcium, activates protein kinase C. Its activation has been implicated in several steps of atheroma plaque formation [26][30][34]. Furthermore, people with diabetes have qualitative and quantitative changes in the lipoprotein metabolism that have been implicated in the process of atherogenesis [35][36][37]. Most of the above processes are interrelated and promote each other. This perpetuates and accelerates the process of atherosclerosis.
Finally, people with diabetes not only have a greater atherosclerotic burden than the general population [38], but also have a greater inflammatory infiltrate, necrotic core and calcification that have been linked with increased plaque vulnerability [39]. Several of these changes are due to hyperglycaemia, but the high residual risk indicates that other agents are also involved. Even a recent Mendelian randomisation study suggests a possible causal role of T1D in peripheral and coronary atherosclerosis after adjusting for confounders (comorbidities, classic CVR factors, lipid and inflammatory variables), with a partial mediation of the effect through hypertension [40].

References

  1. Tsao, C.W.; Aday, A.W.; Almarzooq, Z.I.; Anderson, C.A.M.; Arora, P.; Avery, C.L.; Baker-Smith, C.M.; Beaton, A.Z.; Boehme, A.K.; Buxton, A.E.; et al. Heart Disease and Stroke Statistics—2023 Update: A Report from the American Heart Association. Circulation 2023, 147, E93–E621.
  2. Vaduganathan, M.; Mensah, G.A.; Turco, J.V.; Fuster, V.; Roth, G.A. The Global Burden of Cardiovascular Diseases and Risk. J. Am. Coll. Cardiol. 2022, 80, 2361–2371.
  3. Mortensen, M.B.; Tybjærg-Hansen, A.; Nordestgaard, B.G. Statin Eligibility for Primary Prevention of Cardiovascular Disease According to 2021 European Prevention Guidelines Compared with Other International Guidelines. JAMA Cardiol. 2022, 7, 836–843.
  4. Damen, J.A.; Pajouheshnia, R.; Heus, P.; Moons, K.G.M.; Reitsma, J.B.; Scholten, R.J.P.M.; Hooft, L.; Debray, T.P.A. Performance of the Framingham Risk Models and Pooled Cohort Equations for Predicting 10-Year Risk of Cardiovascular Disease: A Systematic Review and Meta-Analysis. BMC Med. 2019, 17, 109.
  5. Kavousi, M.; Leening, M.J.G.; Nanchen, D.; Greenland, P.; Graham, I.M.; Steyerberg, E.W.; Ikram, M.A.; Stricker, B.H.; Hofman, A.; Franco, O.H. Comparison of Application of the ACC/AHA Guidelines, Adult Treatment Panel III Guidelines, and European Society of Cardiology Guidelines for Cardiovascular Disease Prevention in a European Cohort. JAMA 2014, 311, 1416–1423.
  6. Tota-Maharaj, R.; Blaha, M.J.; Blankstein, R.; Silverman, M.G.; Eng, J.; Shaw, L.J.; Blumenthal, R.S.; Budoff, M.J.; Nasir, K. Association of Coronary Artery Calcium and Coronary Heart Disease Events in Young and Elderly Participants in the Multi-Ethnic Study of Atherosclerosis: A Secondary Analysis of a Prospective, Population-Based Cohort. Mayo Clin. Proc. 2014, 89, 1350–1359.
  7. Nambi, V.; Chambless, L.; Folsom, A.R.; He, M.; Hu, Y.; Mosley, T.; Volcik, K.; Boerwinkle, E.; Ballantyne, C.M. Carotid Intima-Media Thickness and Presence or Absence of Plaque Improves Prediction of Coronary Heart Disease Risk: The ARIC (Atherosclerosis Risk In Communities) Study. J. Am. Coll. Cardiol. 2010, 55, 1600–1607.
  8. Peters, S.A.E.; Den Ruijter, H.M.; Bots, M.L.; Moons, K.G.M. Improvements in Risk Stratification for the Occurrence of Cardiovascular Disease by Imaging Subclinical Atherosclerosis: A Systematic Review. Heart 2012, 98, 177–184.
  9. Mendieta, G.; Pocock, S.; Mass, V.; Moreno, A.; Owen, R.; García-Lunar, I.; López-Melgar, B.; Fuster, J.J.; Andres, V.; Pérez-Herreras, C.; et al. Determinants of Progression and Regression of Subclinical Atherosclerosis Over 6 Years. J. Am. Coll. Cardiol. 2023, 82, 2069–2083.
  10. Carr, J.J.; Jacobs, D.R.; Terry, J.G.; Shay, C.M.; Sidney, S.; Liu, K.; Schreiner, P.J.; Lewis, C.E.; Shikany, J.M.; Reis, J.P.; et al. Association of Coronary Artery Calcium in Adults Aged 32 to 46 Years with Incident Coronary Heart Disease and Death. JAMA Cardiol. 2017, 2, 391–399.
  11. Nissen, S.E.; Nicholls, S.J.; Sipahi, I.; Libby, P.; Raichlen, J.S.; Ballantyne, C.M.; Davignon, J.; Erbel, R.; Fruchart, J.C.; Tardif, J.C.; et al. Effect of Very High-Intensity Statin Therapy on Regression of Coronary Atherosclerosis: The ASTEROID Trial. JAMA 2006, 295, 1556–1565.
  12. Nicholls, S.J.; Puri, R.; Anderson, T.; Ballantyne, C.M.; Cho, L.; Kastelein, J.J.P.; Koenig, W.; Somaratne, R.; Kassahun, H.; Yang, J.; et al. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA 2016, 316, 2373–2384.
  13. Räber, L.; Ueki, Y.; Otsuka, T.; Losdat, S.; Häner, J.D.; Lonborg, J.; Fahrni, G.; Iglesias, J.F.; Van Geuns, R.J.; Ondracek, A.S.; et al. Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients with Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial. JAMA 2022, 327, 1771–1781.
  14. Visseren, F.; Mach, F.; Smulders, Y.M.; Carballo, D.; Koskinas, K.C.; Bäck, M.; Benetos, A.; Biffi, A.; Boavida, J.M.; Capodanno, D.; et al. 2021 ESC Guidelines on Cardiovascular Disease Prevention in Clinical Practice: Developed by the Task Force for Cardiovascular Disease Prevention in Clinical Practice with Representatives of the European Society of Cardiology and 12 Medical Societies with the Special Contribution of the European Association of Preventive Cardiology (EAPC). Eur. Heart J. 2021, 42, 3227–3337.
  15. Arnett, D.K.; Blumenthal, R.S.; Albert, M.A.; Buroker, A.B.; Goldberger, Z.D.; Hahn, E.J.; Himmelfarb, C.D.; Khera, A.; Lloyd-Jones, D.; McEvoy, J.W.; et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019, 140, e596–e646.
  16. Näslund, U.; Ng, N.; Lundgren, A.; Fhärm, E.; Grönlund, C.; Johansson, H.; Lindahl, B.; Lindahl, B.; Lindvall, K.; Nilsson, S.K.; et al. Visualization of Asymptomatic Atherosclerotic Disease for Optimum Cardiovascular Prevention (VIPVIZA): A Pragmatic, Open-Label, Randomised Controlled Trial. Lancet 2019, 393, 133–142.
  17. Rawshani, A.; Rawshani, A.; Franzén, S.; Eliasson, B.; Svensson, A.-M.; Miftaraj, M.; McGuire, D.K.; Sattar, N.; Rosengren, A.; Gudbjörnsdottir, S. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. N. Engl. J. Med. 2017, 376, 1407–1418.
  18. Harjutsalo, V.; Pongrac Barlovic, D.; Groop, P.H. Long-Term Population-Based Trends in the Incidence of Cardiovascular Disease in Individuals with Type 1 Diabetes from Finland: A Retrospective, Nationwide, Cohort Study. Lancet Diabetes Endocrinol. 2021, 9, 575–585.
  19. Lind, M.; Svensson, A.-M.; Kosiborod, M.; Gudbjörnsdottir, S.; Pivodic, A.; Wedel, H.; Dahlqvist, S.; Clements, M.; Rosengren, A. Glycemic Control and Excess Mortality in Type 1 Diabetes. N. Engl. J. Med. 2014, 371, 1972–1982.
  20. Vergès, B. Cardiovascular Disease in Type 1 Diabetes, an Underestimated Danger: Epidemiological and Pathophysiological Data. Atherosclerosis 2023. Online ahead of print.
  21. Sousa, G.R.; Pober, D.; Galderisi, A.; Lv, H.J.; Yu, L.; Pereira, A.C.; Doria, A.; Kosiborod, M.; Lipes, M.A. Glycemic Control, Cardiac Autoimmunity, and Long-Term Risk of Cardiovascular Disease in Type 1 Diabetes Mellitus. Circulation 2019, 139, 730–743.
  22. Förstermann, U.; Xia, N.; Li, H. Roles of Vascular Oxidative Stress and Nitric Oxide in the Pathogenesis of Atherosclerosis. Circ. Res. 2017, 120, 713–735.
  23. Foote, C.A.; Soares, R.N.; Ramirez-Perez, F.I.; Ghiarone, T.; Aroor, A.; Manrique-Acevedo, C.; Padilla, J.; Martinez-Lemus, L. Endothelial Glycocalyx. Compr. Physiol. 2022, 12, 3781.
  24. Gudgeon, J.; Marín-Rubio, J.L.; Trost, M. The Role of Macrophage Scavenger Receptor 1 (MSR1) in Inflammatory Disorders and Cancer. Front. Immunol. 2022, 13, 1012002.
  25. Libby, P.; Buring, J.E.; Badimon, L.; Hansson, G.K.; Deanfield, J.; Bittencourt, M.S.; Tokgözoğlu, L.; Lewis, E.F. Atherosclerosis. Nat. Rev. Dis. Primers 2019, 5, 1–18.
  26. Katakami, N. Mechanism of Development of Atherosclerosis and Cardiovascular Disease in Diabetes Mellitus. J. Atheroscler. Thromb. 2018, 25, 27.
  27. Genuth, S.; Sun, W.; Cleary, P.; Sell, D.R.; Dahms, W.; Malone, J.; Sivitz, W.; Monnier, V.M. Glycation and Carboxymethyllysine Levels in Skin Collagen Predict the Risk of Future 10-Year Progression of Diabetic Retinopathy and Nephropathy in the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications Participants with Type 1 Diabetes. Diabetes 2005, 54, 3103–3111.
  28. Osawa, S.; Katakami, N.; Kuroda, A.; Takahara, M.; Sakamoto, F.; Kawamori, D.; Matsuoka, T.; Matsuhisa, M.; Shimomura, I. Skin Autofluorescence Is Associated with Early-Stage Atherosclerosis in Patients with Type 1 Diabetes. J. Atheroscler. Thromb. 2017, 24, 312.
  29. Katakami, N.; Kaneto, H.; Hao, H.; Umayahara, Y.; Fujitani, Y.; Sakamoto, K.; Gorogawa, S.I.; Yasuda, T.; Kawamori, D.; Kajimoto, Y.; et al. Role of Pim-1 in Smooth Muscle Cell Proliferation. J. Biol. Chem. 2004, 279, 54742–54749.
  30. Yuan, T.; Yang, T.; Chen, H.; Fu, D.; Hu, Y.; Wang, J.; Yuan, Q.; Yu, H.; Xu, W.; Xie, X. New Insights into Oxidative Stress and Inflammation during Diabetes Mellitus-Accelerated Atherosclerosis. Redox Biol. 2019, 20, 247.
  31. Mariaca, K.; Serés-Noriega, T.; Viñals, C.; Perea, V.; Conget, I.; Mesa, A.; Boswell, L.; Font, C.; Pané, A.; Vinagre, I.; et al. Neutrophil-to-Lymphocyte Ratio Is Independently Associated with Carotid Atherosclerosis Burden in Individuals with Type 1 Diabetes. Nutr. Metab. Cardiovasc. Dis. 2023. Online ahead of print.
  32. Serés-Noriega, T.; Giménez, M.; Perea, V.; Blanco, J.; Vinagre, I.; Pané, A.; Ruiz, S.; Cofán, M.; Mesa, A.; Esmatjes, E.; et al. Quantification of Glycoproteins by Nuclear Magnetic Resonance Associated with Preclinical Carotid Atherosclerosis in Patients with Type 1 Diabetes. Nutr. Metab. Cardiovasc. Dis. 2021, 31, 2099–2108.
  33. Janssen, A.W.M.; Van Heck, J.I.P.; Stienstra, R.; Aarntzen, E.H.J.G.; Van Diepen, J.A.; Riksen, N.P.; Tack, C.J. Arterial Wall Inflammation Assessed by 18F-FDG-PET/CT Is Higher in Individuals with Type 1 Diabetes and Associated with Circulating Inflammatory Proteins. Cardiovasc. Res. 2023, 119, 1942–1951.
  34. Das Evcimen, N.; King, G.L. The Role of Protein Kinase C Activation and the Vascular Complications of Diabetes. Pharmacol. Res. 2007, 55, 498–510.
  35. Amor, A.J.; Castelblanco, E.; Hernández, M.; Gimenez, M.; Granado-Casas, M.; Blanco, J.; Soldevila, B.; Esmatjes, E.; Conget, I.; Alonso, N.; et al. Advanced Lipoprotein Profile Disturbances in Type 1 Diabetes Mellitus: A Focus on LDL Particles. Cardiovasc. Diabetol. 2020, 19, 126.
  36. Serés-Noriega, T.; Ortega, E.; Giménez, M.; Perea, V.; Boswell, L.; Mariaca, K.; Font, C.; Mesa, A.; Viñals, C.; Blanco, J.; et al. Advanced Lipoprotein Profile Identifies Atherosclerosis Better than Conventional Lipids in Type 1 Diabetes at High Cardiovascular Risk. Nutr. Metab. Cardiovasc. Dis. 2023, 33, 1235–1244.
  37. Vergès, B. Dyslipidemia in Type 1 Diabetes: A Masked Danger. Trends Endocrinol. Metab. 2020, 31, 422–434.
  38. Wang, P.; Xu, Y.Y.; Lv, T.T.; Guan, S.Y.; Li, X.M.; Li, X.P.; Pan, H.F. Subclinical Atherosclerosis in Patients with Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Angiology 2018, 70, 141–159.
  39. Yahagi, K.; Kolodgie, F.D.; Lutter, C.; Mori, H.; Romero, M.E.; Finn, A.V.; Virmani, R. Pathology of Human Coronary and Carotid Artery Atherosclerosis and Vascular Calcification in Diabetes Mellitus. Arterioscler. Thromb. Vasc. Biol. 2017, 37, 191–204.
  40. Liu, Z.; Wang, H.; Yang, Z.; Lu, Y.; Zou, C. Causal Associations between Type 1 Diabetes Mellitus and Cardiovascular Diseases: A Mendelian Randomization Study. Cardiovasc. Diabetol. 2023, 22, 236.
More
Information
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register : , ,
View Times: 55
Revisions: 2 times (View History)
Update Date: 27 Feb 2024
1000/1000